Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VC Deals Analysis: Asia Investors Pour Money Into Grail And May's Other Big Deals

Executive Summary

Asian investors' unrelenting pursuit of medtech ventures continued to crescendo in May. The participants in the largest round so far this year, the $300m series C by Illumina spin-out Grail, are all China-based funds.

You may also be interested in...



Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines

The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.

Grail Encouraged By New Circulating Cell-free Genome Atlas Data

A sub-analysis of the Circulating Cell-free Genome Atlas study show Grail's genome-sequencing technology may be able to detect early-stage lung cancer through DNA signals in the blood.

VC Deals Analysis: 2018 Off To A Flying Start

Venture financing activity hit the ground running in 2018 after a bumper haul of mega-raises brought the total deal value for January close to $1bn.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel